
CX-2051 Proves Safe and Effective in Advanced Colon Cancer
Treatment with the epithelial cell adhesion molecule (EpCAM) PROBODY antibody-drug conjugate CX-2051 demonstrated responses in patients with advanced, late-line colorectal cancer, according to interim phase 1 data from the ongoing CTMX-2051-101 study which …